INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging securities fraud and unlawful business practices related to the company's clinical trial results and stock price decline [1]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Mereo and certain officers/directors engaged in securities fraud or other unlawful business practices [1]. - Investors who purchased Mereo securities during the Class Period have until April 6, 2026, to request to be appointed as Lead Plaintiff [1]. Group 2: Clinical Trial Results - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical announced that the Phase 3 Orbit study was progressing toward a final analysis, which led to a 42.52% drop in Mereo's ADR price, closing at $1.69 per share on July 10, 2025 [1]. - On December 29, 2025, Mereo announced that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, resulting in an 87.7% decline in ADR price, closing at $0.29 per ADR [1].